Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants
Sponsor: Yuhan Corporation
Summary
This is a randomized, double-blind, first-in-human study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of YH35995
Official title: A First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Oral Administration of YH35995 in Healthy Adult Male Participants
Key Details
Gender
MALE
Age Range
19 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
86
Start Date
2024-07-29
Completion Date
2027-06
Last Updated
2025-11-21
Healthy Volunteers
Yes
Conditions
Interventions
YH35995
Oral administration of YH35995
Placebo
Oral administration of Placebo
Locations (1)
CHA Bundang Medical Center
Seongnam, Bundang-gu, South Korea